The Survival Outcomes of Patients With NF1 Associated High-grade Glioma Treated With MEK Inhibitors (P3-6.007)

Tracy Ming-Chun Yu; Aileen Hsi; Aqsa Adnan; Stephanie Knight; J Slopis; Carlos Kamiya-Matsuoka

doi:10.1212/wnl.0000000000215011

June 9, 2026Neurology

The Survival Outcomes of Patients With NF1 Associated High-grade Glioma Treated With MEK Inhibitors (P3-6.007)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to investigate the survival advantage linked to MEK inhibitor therapy in patients with NF1 associated high-grade gliomas.
Investigated patients with neurofibromatosis type 1 and high-grade gliomas.
Evaluated survival outcomes following MEK inhibitor treatment.
Patients receiving MEK inhibitors showed improved survival rates compared to historical controls.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Investigates survival advantage of MEK inhibitors in NF1 high-grade glioma, suggesting potential therapy benefit.

Abstract

To investigate the survival advantage associated with MEK inhibitor (MEKi) therapy in patients with neurofibromatosis type 1 (NF1) associated high-grade glioma (HGGs).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yu et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf300faef96ed7f0558a3 https://doi.org/10.1212/wnl.0000000000215011

View at Publisher

Ask AI

Bookmark

Share

The Survival Outcomes of Patients With NF1 Associated High-grade Glioma Treated With MEK Inhibitors (P3-6.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

The Survival Outcomes of Patients With NF1 Associated High-grade Glioma Treated With MEK Inhibitors (P3-6.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading